Targeting tumor microenvironmental barriers to enhance immunogenic cell death in solid tumors.

In PEMBRO-RT, the ORR at 12 weeks was 36% vs 18% (P = 0.07), median PFS 6.6 vs 1.9 months (HR 0.71; P = 0.19), and median OS 15.9 vs 7.6 months (HR 0.66; P = 0.16) for pembrolizumab + SBRT versus pembrolizumab alone; although numerical improvements were observed, differences did not reach statistical significance, with the largest signal seen in PD-L1-negative tumors ( 47 ).

also in 111,027 other papers